Literature DB >> 16960901

Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients.

Manuela Indelicato1, Valentina Chiarenza, Massimo Libra, Grazia Malaponte, Valentina Bevelacqua, Maurizio Marchini, James A McCubrey, Franca Stivala, Raffaella Scorza, Maria Clorinda Mazzarino.   

Abstract

Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and internal organs fibrosis due to an extracellular matrix (ECM) accumulation of type I collagen. The turnover of the ECM is dependent on the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs). The disruption of this balance is involved in SSc because higher serum TIMP-1 levels have been demonstrated in SSc patients than in controls. On this basis, we analyzed three polymorphisms: -19A>G, +261C>T, and +372T>C of the TIMP-1 gene in SSc patients (67 females, eight males) and controls (29 females, nine males). The C allele of the +372T>C single nucleotide polymorphism (SNP) was observed at a higher frequency in male patients than in healthy individuals (P=0.02), while no differences were observed in the female subjects. Our findings suggest that the +372T>C polymorphism of the TIMP-1 gene is associated with SSc in male individuals. No association with the clinical characteristics of SSc Italian patients and TIMP-1 gene polymorphisms was observed. Thus, the role of TIMP-1 gene in predisposition to SSc remains controversial.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960901      PMCID: PMC6807471          DOI: 10.1002/jcla.20128

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  15 in total

1.  Stromelysin promoter polymorphism is associated with systemic sclerosis.

Authors:  B Marasini; S Casari; S Zeni; O Turri; M L Biondi
Journal:  Rheumatology (Oxford)       Date:  2001-04       Impact factor: 7.580

Review 2.  The role of infectious agents in the pathogenesis of systemic sclerosis.

Authors:  Damir Hamamdzic; Laura M Kasman; E Carwile LeRoy
Journal:  Curr Opin Rheumatol       Date:  2002-11       Impact factor: 5.006

3.  Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts.

Authors:  K Kikuchi; T Kadono; M Furue; K Tamaki
Journal:  J Invest Dermatol       Date:  1997-03       Impact factor: 8.551

4.  Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis.

Authors:  K Kuroda; H Shinkai
Journal:  Arch Dermatol Res       Date:  1997-09       Impact factor: 3.017

5.  Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture.

Authors:  J Uitto; E A Bauer; A Z Eisen
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

6.  Association of markers for TGFbeta3, TGFbeta2 and TIMP1 with systemic sclerosis.

Authors:  E Susol; A L Rands; A Herrick; N McHugh; J H Barrett; W E Ollier; J Worthington
Journal:  Rheumatology (Oxford)       Date:  2000-12       Impact factor: 7.580

7.  Lack of association of a functionally relevant single nucleotide polymorphism of matrix metalloproteinase-1 promoter with systemic sclerosis (scleroderma).

Authors:  R W Johnson; J D Reveille; T McNearney; M Fischbach; A W Friedman; C Ahn; F C Arnett; F K Tan
Journal:  Genes Immun       Date:  2001-08       Impact factor: 2.676

Review 8.  Epidemiology and pathogenesis of scleroderma.

Authors:  Keng Chen; Adrian See; Stephen Shumack
Journal:  Australas J Dermatol       Date:  2003-02       Impact factor: 2.875

9.  Tissue inhibitor of metalloproteinases-1, -2, and -3 polymorphisms in a white population with intracranial aneurysms.

Authors:  Dietmar Krex; Henning Röhl; Inke R König; Andreas Ziegler; Hans K Schackert; Gabriele Schackert
Journal:  Stroke       Date:  2003-11-06       Impact factor: 7.914

10.  Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells.

Authors:  Shinichi Sato; Manabu Fujimoto; Minoru Hasegawa; Kazukiko Takehara
Journal:  Arthritis Rheum       Date:  2004-06
View more
  6 in total

1.  Role of tissue inhibitor of metalloproteinases-1 in the development of autoimmune lymphoproliferation.

Authors:  Elena Boggio; Manuela Indelicato; Elisabetta Orilieri; Riccardo Mesturini; Maria Clorinda Mazzarino; Maria Francesca Campagnoli; Ugo Ramenghi; Umberto Dianzani; Annalisa Chiocchetti
Journal:  Haematologica       Date:  2010-06-30       Impact factor: 9.941

Review 2.  Matrix metalloproteinases: a review of their structure and role in systemic sclerosis.

Authors:  Wen-jia Peng; Jun-wei Yan; Ya-nan Wan; Bing-xiang Wang; Jin-hui Tao; Guo-jun Yang; Hai-feng Pan; Jing Wang
Journal:  J Clin Immunol       Date:  2012-07-06       Impact factor: 8.317

3.  The Immunogenetics of Systemic Sclerosis.

Authors:  Begüm Ünlü; Ümit Türsen; Zeynab Rajabi; Navid Jabalameli; Fateme Rajabi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 4.  Association of TIMP-1 and COL4A4 Gene Polymorphisms with Keratoconus in an Iranian Population.

Authors:  Davood Yari; Zohreh Ehsanbakhsh; Mohammad-Hosein Validad; Farzaneh Hasanian Langroudi
Journal:  J Ophthalmic Vis Res       Date:  2020-08-06

5.  Genetic Susceptibility to Systemic Sclerosis in the Greek-Cypriot Population: A Pilot Study.

Authors:  Paraskevi Chairta; Savvas Psarelis; Kyriaki Michailidou; Christiana Demetriou; Sofia Symeonidou; Paschalis Nicolaou; Kyproula Christodoulou
Journal:  Genet Test Mol Biomarkers       Date:  2020-04-21

6.  The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis.

Authors:  Leonardo Lorente; Mar Martín; Fátima Plasencia; Jordi Solé-Violán; José Blanquer; Lorenzo Labarta; César Díaz; Juan María Borreguero-León; Alejandro Jiménez; José Antonio Páramo; Josune Orbe; José A Rodríguez; Eduardo Salido
Journal:  Crit Care       Date:  2013-05-25       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.